A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Inclusion Criteria:

• Male or female participants ≥ 50 and ≤ 85 years of age at time of informed consent.

• Diagnosis of mild cognitive impairment OR mild dementia due to either: Parkinson'sdisease associated with REM sleep behavior disorder (RBD+PD) and positive responseto the RBD Single-Question Screen (RBD1Q) and without hallucinations; OR Alzheimer'sDisease (AD).

• For participants taking medications: stable dose and regimen for at least 30 days (90 days for anti-psychotic medications) prior to Day -1 and the dose must remainunchanged through the End of Study Visit unless required for management of adverseevents (AEs).

• Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out).

• Adequate visual and auditory abilities and motor skills to perform all aspects ofthe cognitive and functional assessments.

• Has a spouse or caregiver who can accompany the subject at specified study visits (if required based on cognitive function).

• Montreal Cognitive Assessment (MoCA) score ≥ 14 and ≤ 26.

• Unless confirmed to be azoospermic (vasectomized or secondary to medical cause),males must agree to use a male condom from Day -1 until the End of Study visit whenhaving penile-vaginal intercourse with a woman of childbearing potential who is notcurrently pregnant. Note: Men with a pregnant or breastfeeding partner must agree toremain abstinent from penile-vaginal intercourse or use a condom during each episodeof penile-vaginal penetration until after the End of Study Visit.

• Females of childbearing potential (i.e., not postmenopausal or surgically sterile)who have a male partner must have a negative serum pregnancy test result and mustagree to one of the following from start of Screening through 30 days after the laststudy medication administration: use a highly effective method of birth control; ormonogamous relationship with a male partner of confirmed sterility; or practicecomplete abstinence.

• Females of non-childbearing potential may be enrolled if it is documented that theyare postmenopausal.

• Body weight greater or equal to 50 kg and body mass index (BMI) between 18 and 35kg/m^2, inclusive at Screening.

• Stable medical conditions for 30 days prior to Screening visit (e.g., controlledhypertension, dyslipidemia).

• Willing to follow the protocol requirements and comply with protocol restrictions.

• Capable of providing informed consent and complying with study procedures.

• Able to speak, understand and read English.

Exclusion Criteria:

• Participants with poorly controlled hypertension despite lifestyle modificationsand/or pharmacotherapy.

• Participants with pulmonary disease, including asthma, or evidence of clinicallysignificant moderate or severe pulmonary symptoms.

• Clinical signs indicating syndromes such as corticobasal degeneration, supranucleargaze palsy, multiple system atrophy, chronic traumatic encephalopathy, signs offrontotemporal dementia, history of stroke, head injury or encephalitis, cerebellarsigns, early severe autonomic involvement, or Babinski sign.

• Current evidence of epilepsy, focal brain lesion, head injury with loss ofconsciousness or meeting DSM-V diagnostic criteria for psychotic disorders, such asschizophrenia or bipolar disorder, or have unstable concomitant psychiatricsymptomatology (participants with psychotic disorders may be enrolled if theircondition is effectively managed, i.e., must be receiving stable doses ofanti-psychotic medications(s) 90 days prior to randomization and must remain on thatdose throughout both treatment periods.)

• Evidence of any significant clinical disorder or laboratory finding (e.g., potassiumlevels below normal range) that renders the participant unsuitable for receiving aninvestigational drug including clinically significant or unstable hematologic,moderate and severe impairment of hepatic function (as defined by the NationalCancer Institute Organ Dysfunction Working Group), cardiovascular, pulmonary,gastrointestinal, endocrine (including thyrotoxicosis, excluding managed hypo andhyperthyroidism), immunologic, dermatologic, neurologic, musculoskeletal, metabolic,renal, or other systemic disease or laboratory abnormality.

• Participants with a history of malignant disease within 5 years, including solidtumors and hematologic malignancies (exceptions: [a] basal cell and squamous cellcarcinomas of the skin that have been completely excised and are considered cured; [b] low-grade adenocarcinoma of the prostate, which are slow growing, and areunlikely to progress or metastasize during the clinical trial).

• Any clinically significant medical condition or disease as determined by medicalhistory, physical examination 12-lead electrocardiogram (ECG) and clinicallaboratory assessments conducted that, in the view of the Principal Investigator,will interfere with participation in the study or interpretation of results.

• Clinically significant abnormalities of 12-lead ECG (as determined by a centralreader), including QTcF > 440 ms, for males and females, and/or HR < 50 beats perminute, or evidence of bundle branch blocks, as indicated on the Mean ECG AnalysisReport during the screening Period.

• A calculated creatinine clearance of ≤60 mL/min according to the Cockcroft-Gaultequation.

• Current use of any prohibited prescription medication, over-the-counter medication,or herbal supplements including green tea products during Screening or throughoutstudy, unless approved by both the Investigator and the Sponsor Medical Monitor.

• Prior and/or concurrent treatment with any investigational drug ≤90 days prior todosing (Day 1), or ≤5 half-lives of the drug (whichever is longer), or currentenrollment in any other study treatment or disease study, except for observationalstudies.

• Prior and/or concurrent treatment with any beta-AR agonists or beta-AR blockers (includes oral meds, IV or inhaled) or any meds that impact adrenergic signalingwithin the last month prior to Screening. Participants may be on stable doses ofserotonin-noradrenaline reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs), or any treatment for ADHD including noradrenaline reuptake inhibitors (NRIs), or amphetamines within the last month prior to Screening.

• A history of heart failure, sinus bradycardia, second- or third-degree heart block,hypokalemia, attack of unconsciousness possibly associated with torsades de pointsor family history of Long QT Syndrome.

• Known or suspected alcohol or substance abuse within the past 12 months and/orpositive test for alcohol or drugs of abuse at Screening or Day -1.

• Suicidal ideation with actual intent or plan ("Yes" answer on the C-SSRS ideationitems 4 or 5) within 3 months prior to study Screening.

• Positive screening test for human immunodeficiency virus (HIV), hepatitis C antibody (HCV Ab) or current hepatitis B infection (defined as positive for hepatitis Bsurface antigen [HBsAg] at Screening). Subjects with immunity to hepatitis B (defined as negative HbsAg and positive hepatitis B surface antibody [HbsAb]) areeligible to participate in the study.

• Current infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

• Females who are breastfeeding.

• Any other reason for which the PI considers it is not in the best interest of theparticipant to undertake the study.